- Home
- ALLT vs RIGL Comparison
ALLT vs RIGL Comparison
Compare ALLT & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLT
- RIGL
- Stock Information
- Founded
- ALLT 1996
- RIGL 1996
- Country
- ALLT Israel
- RIGL United States
- Employees
- ALLT N/A
- RIGL N/A
- Industry
- ALLT Telecommunications Equipment
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- ALLT Telecommunications
- RIGL Health Care
- Exchange
- ALLT Nasdaq
- RIGL Nasdaq
- Market Cap
- ALLT 342.5M
- RIGL 335.5M
- IPO Year
- ALLT 2006
- RIGL 2000
- Fundamental
- Price
- ALLT $7.86
- RIGL $38.85
- Analyst Decision
- ALLT Buy
- RIGL Buy
- Analyst Count
- ALLT 1
- RIGL 5
- Target Price
- ALLT N/A
- RIGL $38.20
- AVG Volume (30 Days)
- ALLT 535.2K
- RIGL 995.6K
- Earning Date
- ALLT 08-14-2025
- RIGL 08-05-2025
- Dividend Yield
- ALLT N/A
- RIGL N/A
- EPS Growth
- ALLT N/A
- RIGL N/A
- EPS
- ALLT N/A
- RIGL 5.43
- Revenue
- ALLT $95,342,000.00
- RIGL $267,921,000.00
- Revenue This Year
- ALLT $10.64
- RIGL $59.93
- Revenue Next Year
- ALLT $15.76
- RIGL N/A
- P/E Ratio
- ALLT N/A
- RIGL $7.15
- Revenue Growth
- ALLT 4.74
- RIGL 105.62
- 52 Week Low
- ALLT $2.75
- RIGL $12.66
- 52 Week High
- ALLT $10.77
- RIGL $43.72
- Technical
- Relative Strength Index (RSI)
- ALLT 51.18
- RIGL 68.57
- Support Level
- ALLT $7.71
- RIGL $39.00
- Resistance Level
- ALLT $8.10
- RIGL $42.08
- Average True Range (ATR)
- ALLT 0.44
- RIGL 2.32
- MACD
- ALLT 0.09
- RIGL -0.37
- Stochastic Oscillator
- ALLT 59.12
- RIGL 53.26
About ALLT Allot Ltd.
Allot Ltd is a provider of network intelligence and security solutions for service providers and enterprises. The company's solutions are deployed globally for network and application analytics, traffic control and shaping, and network-based security services. The firm's multi-service platforms are deployed by mobile, fixed, and cloud service providers and enterprises. The company has a customer base in Europe, Asia and Oceania, the Americas, the Middle East, and Africa.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.